Triple

T11074225
Position Surface form Disambiguated ID Type / Status
Subject HER2 receptor E261824 entity
Predicate encodedByGene P90097 FINISHED
Object ERBB2 gene E261825 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: ERBB2 gene | Statement: [HER2 receptor, encodedByGene, ERBB2 gene]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: ERBB2 gene
Context triple: [HER2 receptor, encodedByGene, ERBB2 gene]
  • A. ERBB2 chosen
    ERBB2, also known as HER2, is a receptor tyrosine kinase frequently overexpressed in certain breast and other cancers and serves as a key therapeutic target.
  • B. HER2 receptor
    The HER2 receptor is a cell surface protein and member of the epidermal growth factor receptor family that, when overexpressed, drives the growth of certain aggressive breast and other cancers.
  • C. EGFR
    EGFR (epidermal growth factor receptor) is a transmembrane receptor tyrosine kinase that regulates cell growth and survival and is frequently implicated in cancer development and progression.
  • D. ERBB3
    ERBB3 is a member of the ErbB family of receptor tyrosine kinases that plays a key role in cell signaling, particularly in cancer, often through potent mitogenic and survival pathways.
  • E. CDK4
    CDK4 is a cyclin-dependent kinase that regulates cell cycle progression and is a key therapeutic target in certain cancers.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d6aa9983c08190b0ef61603b69feac completed April 8, 2026, 7:20 p.m.
NER Named-entity recognition batch_69d7994e32fc8190a6591d9e82b68f75 completed April 9, 2026, 12:19 p.m.
NED1 Entity disambiguation (via context triple) batch_69e3e76a49fc8190945f4770bf808b43 completed April 18, 2026, 8:19 p.m.
Created at: April 8, 2026, 9:26 p.m.